Who makes VB-1953 - 2%?

VB-1953 - 2% is developed by Vyome Therapeutics Inc..

Last reviewed 2026-04-19 · How we verify

VB-1953 - 2%

Vyome Therapeutics Inc. · Phase 2 active Small molecule

At a glance

Generic name	VB-1953 - 2%
Sponsor	Vyome Therapeutics Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VB-1953 - 2% CI brief — competitive landscape report
VB-1953 - 2% updates RSS · CI watch RSS
Vyome Therapeutics Inc. portfolio CI